Question 1: Co-trimoxazole dosing dilemma: what is the right dose?

Boast, Alison; Osowicki, Joshua; Cole, Theresa; Curtis, Nigel; Gwee, Amanda

doi:10.1136/archdischild-2015-309100

Cited by 2 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Start broad‐spectrum antibiotics, such as meropenem plus P jiroveci treatment with high‐dose trimethoprim‐sulphamethoxazole 20 mg/kg/d, calculated for trimethoprim, divided into three doses . Note the high dose needed for P jiroveci treatment compared with treatment for other infections …”

Section: Resultsmentioning

confidence: 99%

An overview of how on‐call consultant paediatricians can recognise and manage severe primary immunodeficiencies

et al. 2019

View full text Add to dashboard Cite

Severe primary paediatric immunodeficiency syndromes are rare and potentially fatal unless suspected, diagnosed and treated early. We provide clinical guidance and support for on‐call consultant paediatricians working in secondary level hospitals on how to recognise and manage children with these conditions. Our paper addresses four conditions that risk the most severe outcomes if they are not adequately cared for during on‐call periods, such as weekends: severe combined immunodeficiency, haemophagocytic lymphohistiocytosis, severe congenital neutropaenia and chronic granulomatous disease. Conclusion On‐call paediatricians are provided with advice on handling the most severe primary immunodeficiencies.

show abstract

Section: Resultsmentioning

confidence: 99%

An overview of how on‐call consultant paediatricians can recognise and manage severe primary immunodeficiencies

et al. 2019

View full text Add to dashboard Cite

show abstract

Position statement on infection screening, prophylaxis, and vaccination in pediatric patients with rheumatic diseases and immunosuppressive therapies, part 2: infection prophylaxis

et al. 2023

View full text Add to dashboard Cite

This study aims to provide practical recommendations on prophylaxis for infection in pediatric patients with immune-mediated rheumatic diseases receiving/scheduled to receive immunosuppressive therapy. A qualitative approach was applied. A narrative literature review was performed via Medline. Primary searches were conducted using MeSH terms and free text to identify articles that analyzed data on infections and vaccinations in pediatric patients with immune-mediated rheumatic diseases receiving immunosuppressive therapy. The results were presented and discussed in a nominal group meeting comprising a committee of 12 pediatric rheumatologists from the Prevention and Treatment of Infections Working Group of the Spanish Society of Pediatric Rheumatology. Several recommendations were generated. A consensus procedure was implemented via a Delphi process that was extended to members of the Spanish Society of Pediatric Rheumatology and the Vaccine Advisory Committee of the Spanish Association of Pediatrics. Participants produced a score ranging from 0 (completely disagree) to 10 (completely agree). Agreement was considered to have been reached if at least 70% of participants voted ≥ 7. The literature review included more than 400 articles. Overall, 63 recommendations were generated (23 on infection prophylaxis) and voted by 59 pediatric rheumatologists and other pediatric specialists, all of whom achieved the pre-established level of agreement. The recommendations on prophylaxis of infection cover vaccination and prophylaxis against varicella zoster virus, tuberculosis, Pneumocystis jiroveccii, and invasive fungal infections in pediatric patients with immune-mediated rheumatic diseases receiving/scheduled to receive immunosuppressive therapy. Conclusion: Based on current evidence and a Delphi process, we provided consensus and updated recommendations on prophylaxis and treatment of infections to guide those caring for pediatric rheumatology patients. What is Known: •Data largely derived from adults find that infectious diseases and related complications are a major cause of morbidity and mortality in patients with immune-mediated rheumatic diseases. •It is crucial to be aware of the preventive measures that should be implemented to prevent these infections in children, although most guidelines are often extrapolated from adult cases. What is New: •In the absence of evidence, a literature review and a Delphi survey were conducted to establish a series of expert recommendations that could prove useful in clinical practice, providing a practical and simple day-to-day approach to be used by pediatric rheumatologists. •The recommendations focus on tuberculosis, herpes zoster virus, fungal infections, and Pneumocystis jirovecii.

show abstract

Question 1: Co-trimoxazole dosing dilemma: what is the right dose?

Cited by 2 publications

References 19 publications

An overview of how on‐call consultant paediatricians can recognise and manage severe primary immunodeficiencies

An overview of how on‐call consultant paediatricians can recognise and manage severe primary immunodeficiencies

Position statement on infection screening, prophylaxis, and vaccination in pediatric patients with rheumatic diseases and immunosuppressive therapies, part 2: infection prophylaxis

Contact Info

Product

Resources

About